This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
Eastern Cooperative Oncology Group performance status (ECOG PS) with no deterioration over the previous 2 weeks.
Progressive cancer at the time of enrollment.
Adequate organ and marrow function.
Must have evaluable disease.
Major surgery within 4 weeks of the first dose of study intervention.
Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study intervention.
With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study intervention.
Any known history of persisting severe pancytopenia due to any cause.
9
Treatment groupsSee each treatment group below.
AstraZeneca
Lead sponsor